Daewoong Pharmaceutical secures first US patent post-TurnBio acquisition for mRNA delivery tech

Daewoong Pharmaceutical has achieved a significant milestone by securing a US patent decision for its messenger RNA (mRNA) delivery technology. This breakthrough allows mRNA to be delivered efficiently into cells, a crucial step for developing advanced therapies.

The patent decision marks the company's first global patent success since acquiring the intellectual property and assets of US-based TurnBio Biotechnology in May. This strategic acquisition has clearly accelerated Daewoong's progress in the competitive field of mRNA technology.

Daewoong plans to leverage this patented technology to develop novel mRNA-based therapies, with a particular focus on anti-aging treatments. The company aims to lead the next generation of regenerative medicine through innovative research and development.

This achievement underscores Daewoong Pharmaceutical's commitment to advancing biotechnology and expanding its global presence. The successful integration of TurnBio's expertise and assets is now translating into tangible results, positioning the company for future growth in the biopharmaceutical sector.